메뉴 건너뛰기




Volumn 156, Issue 2, 2012, Pages 213-224

CD48 as a novel molecular target for antibody therapy in multiple myeloma

Author keywords

Antibody therapy; CD48; Monoclonal antibody; Multiple myeloma; Xenograft model

Indexed keywords

CD34 ANTIGEN; CD48 ANTIBODY; CD48 ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

EID: 84155195009     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08941.x     Document Type: Article
Times cited : (37)

References (45)
  • 5
    • 1842579580 scopus 로고    scopus 로고
    • A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
    • Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., MacDonald, A.P., Repp, R., Schetelig, J., Seipelt, G. & Osterborg, A. (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood, 103, 2920-2924.
    • (2004) Blood , vol.103 , pp. 2920-2924
    • Enblad, G.1    Hagberg, H.2    Erlanson, M.3    Lundin, J.4    MacDonald, A.P.5    Repp, R.6    Schetelig, J.7    Seipelt, G.8    Osterborg, A.9
  • 6
    • 0348147649 scopus 로고    scopus 로고
    • An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab
    • discussion 2570-2572
    • Ghobrial, I.M., Otteman, L.A. & White, W.L. (2003) An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. New England Journal of Medicine, 349, 2570-2572. discussion 2570-2572.
    • (2003) New England Journal of Medicine , vol.349 , pp. 2570-2572
    • Ghobrial, I.M.1    Otteman, L.A.2    White, W.L.3
  • 9
    • 0028202976 scopus 로고
    • A pilot clinical trial of two murine monoclonal antibodies fixing human complement in patients with chronic lymphatic leukaemia
    • Greenaway, S., Henniker, A.J., Walsh, M. & Bradstock, K.F. (1994) A pilot clinical trial of two murine monoclonal antibodies fixing human complement in patients with chronic lymphatic leukaemia. Leukaemia & Lymphoma, 13, 323-331.
    • (1994) Leukaemia & Lymphoma , vol.13 , pp. 323-331
    • Greenaway, S.1    Henniker, A.J.2    Walsh, M.3    Bradstock, K.F.4
  • 10
    • 60649093569 scopus 로고    scopus 로고
    • Rediscovering alemtuzumab: current and emerging therapeutic roles
    • Gribben, J.G. & Hallek, M. (2009) Rediscovering alemtuzumab: current and emerging therapeutic roles. British Journal Haematology, 144, 818-831.
    • (2009) British Journal Haematology , vol.144 , pp. 818-831
    • Gribben, J.G.1    Hallek, M.2
  • 11
    • 66449083374 scopus 로고    scopus 로고
    • FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma
    • Hadari, Y. & Schlessinger, J. (2009) FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. Journal of Clinical Investigation, 119, 1077-1079.
    • (2009) Journal of Clinical Investigation , vol.119 , pp. 1077-1079
    • Hadari, Y.1    Schlessinger, J.2
  • 12
    • 0037441880 scopus 로고    scopus 로고
    • Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab
    • Herbert, K.E., Prince, H.M. & Westerman, D.A. (2003) Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab. Blood, 101, 1654.
    • (2003) Blood , vol.101 , pp. 1654
    • Herbert, K.E.1    Prince, H.M.2    Westerman, D.A.3
  • 14
    • 34547106018 scopus 로고    scopus 로고
    • Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
    • Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P.G. & Anderson, K.C. (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer, 7, 585-598.
    • (2007) Nature Reviews Cancer , vol.7 , pp. 585-598
    • Hideshima, T.1    Mitsiades, C.2    Tonon, G.3    Richardson, P.G.4    Anderson, K.C.5
  • 19
    • 51649107160 scopus 로고    scopus 로고
    • EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma
    • Kluin-Nelemans, H.C., Coenen, J.L., Boers, J.E., van Imhoff, G.W. & Rosati, S. (2008) EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood, 112, 1039-1041.
    • (2008) Blood , vol.112 , pp. 1039-1041
    • Kluin-Nelemans, H.C.1    Coenen, J.L.2    Boers, J.E.3    van Imhoff, G.W.4    Rosati, S.5
  • 21
    • 0028127304 scopus 로고
    • Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
    • Maloney, D.G., Liles, T.M., Czerwinski, D.K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A. & Levy, R. (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 84, 2457-2466.
    • (1994) Blood , vol.84 , pp. 2457-2466
    • Maloney, D.G.1    Liles, T.M.2    Czerwinski, D.K.3    Waldichuk, C.4    Rosenberg, J.5    Grillo-Lopez, A.6    Levy, R.7
  • 23
  • 24
    • 56449128746 scopus 로고    scopus 로고
    • New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings
    • Ocio, E.M., Mateos, M.V., Maiso, P., Pandiella, A. & San-Miguel, J.F. (2008) New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncology, 9, 1157-1165.
    • (2008) Lancet Oncology , vol.9 , pp. 1157-1165
    • Ocio, E.M.1    Mateos, M.V.2    Maiso, P.3    Pandiella, A.4    San-Miguel, J.F.5
  • 29
    • 49349107645 scopus 로고    scopus 로고
    • Differential expression of CD150 (SLAM) family receptors by human hematopoietic stem and progenitor cells
    • Sintes, J., Romero, X., Marin, P., Terhorst, C. & Engel, P. (2008) Differential expression of CD150 (SLAM) family receptors by human hematopoietic stem and progenitor cells. Experimental Hematology, 36, 1199-1204.
    • (2008) Experimental Hematology , vol.36 , pp. 1199-1204
    • Sintes, J.1    Romero, X.2    Marin, P.3    Terhorst, C.4    Engel, P.5
  • 30
    • 0031442143 scopus 로고    scopus 로고
    • Detection of a soluble form of the leukocyte surface antigen CD48 in plasma and its elevation in patients with lymphoid leukemias and arthritis
    • Smith, G.M., Biggs, J., Norris, B., Anderson-Stewart, P. & Ward, R. (1997) Detection of a soluble form of the leukocyte surface antigen CD48 in plasma and its elevation in patients with lymphoid leukemias and arthritis. Journal of Clinical Immunology, 17, 502-509.
    • (1997) Journal of Clinical Immunology , vol.17 , pp. 502-509
    • Smith, G.M.1    Biggs, J.2    Norris, B.3    Anderson-Stewart, P.4    Ward, R.5
  • 31
    • 33947633987 scopus 로고    scopus 로고
    • CD38 as a therapeutic target
    • Stevenson, G.T. (2006) CD38 as a therapeutic target. Molecular Medicine, 12, 345-346.
    • (2006) Molecular Medicine , vol.12 , pp. 345-346
    • Stevenson, G.T.1
  • 32
    • 0025980998 scopus 로고
    • Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-Cd38 antibody
    • Stevenson, F.K., Bell, A.J., Cusack, R., Hamblin, T.J., Slade, C.J., Spellerberg, M.B. & Stevenson, G.T. (1991) Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-Cd38 antibody. Blood, 77, 1071-1079.
    • (1991) Blood , vol.77 , pp. 1071-1079
    • Stevenson, F.K.1    Bell, A.J.2    Cusack, R.3    Hamblin, T.J.4    Slade, C.J.5    Spellerberg, M.B.6    Stevenson, G.T.7
  • 34
    • 0031920548 scopus 로고    scopus 로고
    • Preclinical antitumor activity of an antibody against the leukocyte antigen CD48
    • Sun, H., Norris, B.J., Atkinson, K., Biggs, J.C. & Smith, G.M. (1998) Preclinical antitumor activity of an antibody against the leukocyte antigen CD48. Clinical Cancer Research, 4, 895-900.
    • (1998) Clinical Cancer Research , vol.4 , pp. 895-900
    • Sun, H.1    Norris, B.J.2    Atkinson, K.3    Biggs, J.C.4    Smith, G.M.5
  • 35
    • 0033986782 scopus 로고    scopus 로고
    • Antitumour activity of a chimeric antibody against the leucocyte antigen CD48
    • Sun, H., Biggs, J.C. & Smith, G.M. (2000) Antitumour activity of a chimeric antibody against the leucocyte antigen CD48. Cancer Immunology, Immunotherapy, 48, 595-602.
    • (2000) Cancer Immunology, Immunotherapy , vol.48 , pp. 595-602
    • Sun, H.1    Biggs, J.C.2    Smith, G.M.3
  • 40
  • 42
    • 79251581902 scopus 로고    scopus 로고
    • Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
    • van der Veer, M.S., de Weers, M., van Kessel, B., Bakker, J.M., Wittebol, S., Parren, P.W.H.I., Lokhorst, H.M. & Mutis, T. (2011) Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica, 96, 284-290.
    • (2011) Haematologica , vol.96 , pp. 284-290
    • van der Veer, M.S.1    de Weers, M.2    van Kessel, B.3    Bakker, J.M.4    Wittebol, S.5    Parren, P.W.H.I.6    Lokhorst, H.M.7    Mutis, T.8
  • 43
    • 0038281385 scopus 로고    scopus 로고
    • SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intra-bone marrow injection
    • Wang, J., Kimura, T., Asada, R., Harada, S., Yokota, S., Kawamoto, Y., Fujimura, Y., Tsuji, T., Ikehara, S. & Sonoda, Y. (2003) SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intra-bone marrow injection. Blood, 101, 2924-2931.
    • (2003) Blood , vol.101 , pp. 2924-2931
    • Wang, J.1    Kimura, T.2    Asada, R.3    Harada, S.4    Yokota, S.5    Kawamoto, Y.6    Fujimura, Y.7    Tsuji, T.8    Ikehara, S.9    Sonoda, Y.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.